PER.C6 and DSM
The PERCIVIA PER.C6® Development Center (Cambridge, Massachusetts, United States), the joint venture of Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Royal DSM N.V. is now Percivia LLC . This new legal structure was established to transform the company from a development center jointly directed by Crucell and DSM into a fully independent biopharmaceutical company focused on the development of PER.C6®-based biobetter proteins and monoclonal antibodies as well as global licensing of the PER.C6® human cell line for production of third party monoclonal antibodies and other proteins.
DSM and Crucell announce expansion of PERCIVIA PER.C6® biopharmaceutical joint venture (22 Sept 2010)
PER.C6® Technology Advantages
- Human-like glycosylation
- Rapid development
- Regulatory acceptance (BMF)
- High yields
The combination of the PER.C6® human cell line and DSM’s manufacturing services and high-yielding upstream and process step-reducing downstream technologies provides companies with biologic manufacturing solutions help you to reduce cost, risk and time to market.
High Yields
- 8 grams per liter in fed-batch with standard lgG
- 27 grams per liter in XD® with standard lgG
